Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

325.20DKK
3:28am EST
Change (% chg)

kr.1.20 (+0.37%)
Prev Close
kr.324.00
Open
kr.325.20
Day's High
kr.326.70
Day's Low
kr.323.90
Volume
14,349
Avg. Vol
421,728
52-wk High
kr.413.20
52-wk Low
kr.280.80

Chart for

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and... (more)

Overall

Beta: 0.93
Market Cap(Mil.): kr.64,491.49
Shares Outstanding(Mil.): 199.05
Dividend: 8.00
Yield (%): 2.47

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

BRIEF-Lundbeck Says New CEO To Be Named Within Six Months

* INTERIM CEO GOTZSCHE SAYS EXPECTS NEW CEO WILL BE NAMED WITHIN SIX MONTHS

Feb 07 2018

UPDATE 1-Lundbeck's Q4 operating profit falls short of expectations

COPENHAGEN, Feb 7 Danish drugmaker Lundbeck posted weaker than expected fourth quarter operating profit and gave a broad range for its 2018 financial guidance because of a range of uncertainties.

Feb 07 2018

Lundbeck's Q4 operating profit below expectations

COPENHAGEN, Feb 7 Drugmaker Lundbeck's fourth-quarter operating profit came in at 932 million Danish crowns ($155.19 million), undershooting the 1.05 billion expected by analysts in a Reuters poll.

Feb 07 2018

BRIEF-H Lundbeck Enters Research Partnership On Treatment Of Schizophrenia

* LUNDBECK ENTERS RESEARCH PARTNERSHIP ON NOVEL TREATMENT OF SCHIZOPHRENIA

Jan 05 2018

BRIEF-Lundbeck: Brintellix Approved In China

* LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 04 2017

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Nov 17 2017

UPDATE 2-Financials weigh on European stocks as "Trumpflation" hopes fade

* MSCI EMU earnings growth tracking 7 percent (Adds closing prices, comments)

Nov 08 2017

Shares in Denmark's Lundbeck drop as sales of key drugs disappoint

COPENHAGEN, Nov 8 Shares in Danish pharmaceutical firm Lundbeck fell as much as 6.8 percent on Tuesday as third-quarter sales of its newer drugs, such as those to treat bipolar disorder and depression, undershot market expectations.

Nov 08 2017

BRIEF-Lundbeck CEO sees U.S. prices to increase steadily

* INTERIM CEO SAYS EXPECTS U.S. PRICE INCREASES TO CONTINUE AT CURRENT LEVELS GOING FORWARD Further company coverage: (Reporting by Julie Astrid Thomsen)

Nov 08 2017

BRIEF-Lundbeck Q3 EBIT above expectations at DKK 1.42‍​ bln

* LUNDBECK INCREASED OPERATING PROFIT (EBIT) WITH 126% AND EPS BY 182% IN THE FIRST NINE MONTHS OF 2017

Nov 08 2017

Earnings vs. Estimates